Patents by Inventor Lei Ling

Lei Ling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ligand Assisted Chromatography for Metal Ion Separation
    Publication number: 20170166993
    Abstract: Presented herein is a ligand-assisted elution chromatography process for the separation of metal ions using a sorbent. An inorganic sorbent, titania, for example, has three types of adsorption sites: Bronsted acid (BA), Bronsted base (BB), and Lewis acid (LA). At a high pH, the BA sites can interact with the metal ions as a cation exchanger. If a ligand with COO groups is preloaded onto the sorbent, the COO— groups of the ligand can adsorb onto the LA sites. The adsorbed. ligands become strong adsorption sites for the metal ions. If the Langmuir a value for metal ion adsorption is similar to that of metal ion complexation with the ligand in the mobile phase, the different metal ions can be eluted separately with an overall selectivity which is equal to the ratio of the ligand selectivity to the sorbent selectivity.
    Type: Application
    Filed: July 17, 2015
    Publication date: June 15, 2017
    Inventors: Nien-Hwa Linda Wang, Lei Ling
  • Compositions comprising fusion variants of FGF19 polypeptides
    Patent number: 9670260
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: June 6, 2017
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of diabetes
    Patent number: 9580483
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: February 28, 2017
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • CANCER MODELS AND ASSOCIATED METHODS
    Publication number: 20160252497
    Abstract: Models useful in determining whether fibroblast growth factor 19 variant polypeptides having glucose-lowering activity and/or anti-obesity activity also exhibit favorable oncology-related profiles, and methods and uses associated therewith. Also provided are methods of antagonizing the oncogenic activity of FGF19 in a subject and, in certain embodiments, methods of preventing or treating a disease, disorder or condition, such as a FGF19-dependent disease, disorder or condition, or a symptom thereof.
    Type: Application
    Filed: October 27, 2014
    Publication date: September 1, 2016
    Inventor: Lei LING
  • COMPOSITIONS, USES AND METHODS FOR TREATMENT OF METABOLIC DISORDERS AND DISEASES
    Publication number: 20160200788
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: July 14, 2016
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • USES AND METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES
    Publication number: 20160168221
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: June 16, 2016
    Inventors: Lei Ling, Jian Luo
  • USES AND METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES
    Publication number: 20160168217
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: June 16, 2016
    Inventors: Lei Ling, Jian Luo
  • USES AND METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES
    Publication number: 20160166642
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: June 16, 2016
    Inventors: Lei Ling, Jian Luo
  • COMPOSITIONS COMPRISING VARIANTS AND FUSIONS OF FGF19 POLYPEPTIDES
    Publication number: 20160168215
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: December 29, 2015
    Publication date: June 16, 2016
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • USES AND METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES
    Publication number: 20160168219
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: June 16, 2016
    Inventors: Lei Ling, Jian Luo
  • USES AND METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES
    Publication number: 20160168222
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: June 16, 2016
    Inventors: Lei Ling, Jian Luo
  • USES AND METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES
    Publication number: 20160168218
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: June 16, 2016
    Inventors: Lei Ling, Jian Luo
  • METHODS OF USING COMPOSITIONS COMPRISING VARIANTS AND FUSIONS OF FGF19 POLYPEPTIDES FOR REDUCING GLUCOSE LEVELS IN A SUBJECT
    Publication number: 20160168216
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: December 29, 2015
    Publication date: June 16, 2016
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • USES AND METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES
    Publication number: 20160168220
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: June 16, 2016
    Inventors: Lei Ling, Jian Luo
  • Compositions comprising variants and fusions of FGF19 polypeptides
    Patent number: 9290557
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: March 22, 2016
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
    Patent number: 9273107
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: March 1, 2016
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES
    Publication number: 20160045565
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FG-F21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: December 26, 2013
    Publication date: February 18, 2016
    Applicant: NGM Biopharmaceuticals, Inc.
    Inventors: Lei LING, Jian LUO
  • COMPOSITIONS AND METHODS FOR TREATMENT OF METABOLIC DISORDERS AND DISEASES
    Publication number: 20150291677
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: November 26, 2013
    Publication date: October 15, 2015
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • METHODS OF USING COMPOSITIONS COMPRISING VARIANTS AND FUSIONS OF FGF19 POLYPEPTIDES FOR TREATMENT OF METABOLIC DISORDERS AND DISEASES
    Publication number: 20150284442
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: June 18, 2015
    Publication date: October 8, 2015
    Inventors: Lei LING, Darrin Anthony LINDHOUT
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
    Patent number: 9089525
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: July 28, 2015
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout